Oxidative stress battles neuronal Bcl-xL in a fight to the death

Bcl-xL and Neuroprotection

Bcl-xL is an anti-apoptotic protein found on the mitochondrial membrane. Bcl-xL prevents mitochondrionally-dependent death processes by blocking oligomerization of pro-death proteins including Bax and Bak. Although Bcl-xL is present in a broad range of cell types, the role of Bcl-xL in brain cells has been an emphasis of research in recent decades. Bcl-xL is necessary for embryonic development of the brain (Chen et al., 2011; Fogarty et al., 2019). Depletion of Bcl-xL leads to apoptosis of postmitotic neurons and impairs developmental neurogenesis (Fogarty et al., 2019). Conditional knock out of Bcl-xL causes loss of the upper layer of cortical neurons and the CA1–CA3 regions of hippocampal neurons, which eventually leads to neurobehavioral abnormalities (Nakamura et al., 2016). Application of Bcl-xL shRNA in vitro impairs the extension and arborization of primary hippocampal neurites (Park et al., 2015) which may hinder formation of neuronal interconnections. We have shown that impaired neurite outgrowth in neurons lacking Bcl-xL was reversed by depletion of death receptor 6 (DR6) (Park et al., 2015). DR6 is a tumor necrosis factor receptor widely expressed in developing neurons. Binding between DR6 and its ligand, the N-terminus of amyloid precursor protein, activates caspases causing axonal degeneration (Nikolaev et al., 2009). In addition to Bcl-xL, other Bcl2 proteins such as Puma and Bax are required during axon degeneration (Cusack et al., 2013; Geden and Deshmukh, 2016; Simon et al., 2016). Bcl-xL is reported to enhance function of the F, Fo ATP synthase and improve neuronal ATP production (Alavian et al., 2011; Chen et al., 2011), thus Bcl-xL-mediated energy metabolism may favor metabolically demanding processes during neuronal development and growth. Overexpression of Bcl-xL increases recruitment of mitochondria in presynaptic neurons, induces the formation of synapses, and enhances the frequency and amplitude of synaptic currents to promote synaptic function (Li et al., 2008).

In addition to its role in the development and growth of neurons, Bcl-xL also exhibits protective properties against brain-associated diseases, particularly cerebral ischemia; its expression is often found to be increased during stroke and cardiac arrest (Wu et al., 2003). Levels of protection vary by experimental design. However, strategies to retain Bcl-xL have shown a range of 60–90% neuroprotection in both in vitro and in vivo models. Bcl-xL attenuates ischemia-mediated brain injury (Wu et al., 2003). Inhibiting the proteolytic cleavage of Bcl-xL prevents ischemia-induced neuronal loss in CA1 regions of hippocampal neurons, which may hinder formation of neuronal interconnections. We have shown that impaired neurite outgrowth in neurons lacking Bcl-xL was reversed by depletion of death receptor 6 (DR6) (Park et al., 2015). DR6 is a tumor necrosis factor receptor widely expressed in developing neurons. Binding between DR6 and its ligand, the N-terminus of amyloid precursor protein, activates caspases causing axonal degeneration (Nikolaev et al., 2009). In addition to Bcl-xL, other Bcl2 proteins such as Puma and Bax are required during axon degeneration (Cusack et al., 2013; Geden and Deshmukh, 2016; Simon et al., 2016). Bcl-xL is reported to enhance function of the F, Fo ATP synthase and improve neuronal ATP production (Alavian et al., 2011; Chen et al., 2011), thus Bcl-xL-mediated energy metabolism may favor metabolically demanding processes during neuronal development and growth. Overexpression of Bcl-xL increases recruitment of mitochondria in presynaptic neurons, induces the formation of synapses, and enhances the frequency and amplitude of synaptic currents to promote synaptic function (Li et al., 2008).

In addition to its role in the development and growth of neurons, Bcl-xL also exhibits protective properties against brain-associated diseases, particularly cerebral ischemia; its expression is often found to be increased during stroke and cardiac arrest (Wu et al., 2003). Levels of protection vary by experimental design. However, strategies to retain Bcl-xL have shown a range of 60–90% neuroprotection in both in vitro and in vivo models. Bcl-xL attenuates ischemia-mediated brain injury (Wu et al., 2003). Inhibiting the proteolytic cleavage of Bcl-xL prevents ischemia-induced neuronal loss in CA1 regions of hippocampal neurons, which may hinder formation of neuronal interconnections. We have shown that impaired neurite outgrowth in neurons lacking Bcl-xL was reversed by depletion of death receptor 6 (DR6) (Park et al., 2015). DR6 is a tumor necrosis factor receptor widely expressed in developing neurons. Binding between DR6 and its ligand, the N-terminus of amyloid precursor protein, activates caspases causing axonal degeneration (Nikolaev et al., 2009). In addition to Bcl-xL, other Bcl2 proteins such as Puma and Bax are required during axon degeneration (Cusack et al., 2013; Geden and Deshmukh, 2016; Simon et al., 2016). Bcl-xL is reported to enhance function of the F, Fo ATP synthase and improve neuronal ATP production (Alavian et al., 2011; Chen et al., 2011), thus Bcl-xL-mediated energy metabolism may favor metabolically demanding processes during neuronal development and growth. Overexpression of Bcl-xL increases recruitment of mitochondria in presynaptic neurons, induces the formation of synapses, and enhances the frequency and amplitude of synaptic currents to promote synaptic function (Li et al., 2008).

How to cite this article: Park HA, Broman K, Jonas EA (2021) Oxidative stress battles neuronal Bcl-xL in a fight to the death. Neural Regen Res 16(1):12-15.
hippocampal neurons in rodents (Miyawaki et al., 2008; Ofengeim et al., 2012). In vivo delivery of a Bcl-xL fusion protein protects the brain in mice against focal ischemic injury (Cao et al., 2002). Consistent results showing Bcl-xL protection were also found for in vitro models of excitotoxicity (Park et al., 2017) and oxidative stress (Park et al., 2019); these models are known to mimic the effects of cerebral ischemia. In this review, PubMed was searched to retrieve the articles published between 2000–2020.

Bcl-xL functions via formation of a multiprotein complex with its binding partners (Figure 1). Besides the well-known pro-apoptotic Bcl2 family proteins, Bcl-xL binds to various proteins which regulate neuronal function. Lys 87 in the BH3 domain of Bcl-xL interacts with ryanodine receptor 3, a calcium channel found in the brain, and interaction between Bcl-xL and ryanodine receptor 3 inhibits calcium release in primary hippocampal neurons (Vervliet et al., 2015). Bcl-xL shows high affinity to the C-terminal site of inositol 1,4,5-trisphosphate receptor (IP3R) in the endoplasmic reticulum near the calcium channel pore (Monaco et al., 2012). Since calcium is an important second messenger that triggers both neurotransmission and neurotoxicity, Bcl-xL may act as a switch to control neuronal calcium signaling. Bcl-xL binds directly to the β-subunit of F1Fo ATP synthase and enhances efficiency of ATP synthesis (Alavian et al., 2011) and prevents opening of the mitochondrial permeability transition pore in primary neurons (Alavian et al., 2014). Bcl-xL also interacts with DJ-1, a protein encoded by the PARK7 gene (Chen et al., 2019). Our recent study showed that DJ-1 undergoes protein-protein interaction with F1Fo ATP synthase to support neurite outgrowth of dopaminergic neurons (Chen et al., 2019). Bcl-xL may interact with various protein binding partners of F1Fo ATP synthase to govern neuronal energy metabolism. The BH2 domain of Bcl-xL is required to bind Drp1, and a Bcl-xL-Drp1 complex is found bound to clathrin-coated pits supporting the maintenance of endocytic vesicles responsible for re-uptake of neurotransmitters in neurons (Li et al., 2013).

Oxidative Stress and Cleavage of Bcl-xL

Given Bcl-xL’s significant role in protecting the brain during physiological and pathological processes, it is important to understand the mechanisms of upstream signaling that regulate activity and abundance of Bcl-xL. Recently, we reported that oxidative stress is a key regulator of intracellular Bcl-xL balance in neurons. Primary hippocampal neurons challenged with hydrogen peroxide have significantly increased post-translational cleavage of Bcl-xL (Park et al., 2019). Hydrogen peroxide increases both the activity and abundance of caspase 3, the key protease which cleaves full length Bcl-xL to its N-terminal truncated form ΔN-Bcl-xL (Park et al., 2019). Accumulation of ΔN-Bcl-xL is known to cause mitochondrial dysfunction including abnormal mitochondrial ion channel activity and conductance, mitochondrial membrane potential loss, and impaired ATP production, all of which contribute to neuronal death (Jonas et al., 2004; Ofengeim et al., 2012; Park et al., 2017; Park and Jonas, 2017).

Since mitochondria consume oxygen for oxidative phosphorylation, mitochondria play a major role in generating reactive oxygen species (ROS) (Murphy, 2009). Studies show that ROS cause an increase in the protein level and activity of caspase 3 (Park et al., 2019). In addition, caspase 3 is reported to translocate to mitochondria, where Bcl-xL is localized (Chandra and Tang, 2003). Therefore, ROS are an important upstream control of Bcl-xL and ΔN-Bcl-xL balance due to their regulation of caspase 3, and application of antioxidants may be effective in manipulating Bcl-xL and ΔN-Bcl-xL profiles in neurons (Park et al., 2019). Although caspase 3 has been frequently studied for its role to cleave Bcl-xL during brain disease, other proteases such as calpains may also contribute to Bcl-xL cleavage during events that raise intracellular calcium levels (Gil-Parrado et al., 2002; Liu et al., 2009). Application of calpain inhibitors rescues neurons against oxidative stress-mediated death (See and Loeffler, 2001; D’Orsi et al., 2012). Additionally, Dho et al. (2013) reported that asparagine residues in Bcl-xL undergo deamination, and inhibition of deamination at Asn 52 and 66 prevents calpain-dependent Bcl-xL degradation. Since Asp 61 and 76 are a target of caspase 3 (Clem et al., 1998; Basanez et al., 2001; Ofengeim et al., 2012), the calpain-mediated cleavage product of Bcl-xL may exhibit ΔN-Bcl-xL-like neurotoxic effects. It would be of interest to investigate how other Bcl-xL cleavage products influence neuronal survival under ROS challenge in the future.

Oxidative Stress and Phosphorylation of Bcl-xL

The activity of Bcl-xL is influenced by phosphorylation and dephosphorylation. Amino acid residues of Bcl-xL including Ser 49, Thr 69, and Ser 73 undergo phosphorylation (Gil-Parrado et al., 2002; Arena et al., 2013; Baruah et al., 2016; Megyesi et al., 2016). In particular, Ser 62 is subject to various kinases and has been proposed as an important site for regulation of neuronal function. PTEN-induced kinase 1 (PINK1), a mitochondrial serine/threonine-protein kinase, directly binds and phosphorylates Bcl-xL (Arena et al., 2013). PINK1-dependent phosphorylation of Ser 62 causes Bcl-xL to be resistant to cleavage at Asp 61 and thus inhibits formation of ΔN-Bcl-xL (Arena et al., 2013). Studies have shown that ROS are regulators of PINK1. CCCP-induced oxidative stress causes PINK1-dependent mitophagy (Xiao et al., 2017). Mutations in PINK1 increase the accumulation of ROS, alter mitochondrial morphology, and trigger mitochondrially-dependent apoptosis in dopaminergic SH-SY5Y cells in vitro (Yuan et al., 2010). In vivo models using PINK1 knockout mice show increased lipid peroxidation and depletion of antioxidant pools and associated mitochondrial dysfunction (Billia et al., 2011). The Ser 62 residue on Bcl-xL also has a role in cyclin-dependent kinase-1 (Cdk1)-mediated phosphorylation during oxidative stress (Veas-Pérez de Tudela et al., 2015). Phosphorylation of Bcl-xL at Ser 62 dissociates Bcl-xL from the F1Fo ATP synthase complex, decreasing activity of the F1Fo ATP synthase to support neurite outgrowth and enhances synaptic plasticity and functional recovery upon injury.
Oxidative Stress and Transcription of Bcl-xL

In addition to oxidative stress regulating post-translational modification of Bcl-xL, treatment with H$_2$O$_2$ has been shown to decrease Bcl-xL mRNA expression in vitro, leading to a decline in Bcl-xL protein level (Wang et al., 2015; Wu et al., 2016). Although there are limited studies explaining the underlying mechanisms, oxidative stress may also govern post-transcriptional regulation of Bcl-xL. MicroRNAs (miRNA) are short non-coding RNAs that bind to the target mRNA inhibiting its translation. Wang et al. (2015) found that ROS causes oxidative modification of miR-184, and oxidized miR-184 interacts with Bcl-xL mRNA, suppressing Bcl-xL protein levels. Due to miR-184’s high level in the brain (Danis et al., 2016; Mendes-Silva et al., 2019), preventing miR-184 oxidation may be an effective therapeutic strategy to protect the brain against ROS-associated pathology.

Oxidative stress may also contribute to splicing of Bcl-xL pre-mRNA. The bcl-x gene is spliced into one of two isoforms: anti-apoptotic Bcl-xL, or pro-apoptotic Bcl-xS (Stevens and Oltean, 2019). Bcl-xS is structurally similar to Bcl-xL but contains only a BH3, BH4, and transmembrane domain. Bcl-xS undergoes dimerization in mitochondria (Lindenboim et al., 2001) causing intrinsic apoptosis. Due to its unique chemical structure containing BH4, but lacking BH1 and BH2 domains, Bcl-xS-mediated apoptosis is independent from mechanisms induced by other pro-apoptotic Bcl2 proteins (Lindenboim et al., 2000). However, both Bcl-xS and ΔN-Bcl-xL production occur during apoptosis in a caspase dependent manner (Williott et al., 2011), and Bcl-xS binds directly to Bcl-xL (Lindenboim et al., 2001). Therefore, conditions that enhance Bcl-xS contribute to limiting the pro-survival function of Bcl-xL.

CUG-binding protein 1 (CUGBP1) is a key splicing factor responsible for regulating Bcl-xL/Bcl-xS ratio: overexpression of CUGBP1 increases the proportion of Bcl-xL whereas depletion of CUGBP1 decreases Bcl-xL (Xiao et al., 2012). Xiao et al. (2012) showed that rat oligodendrocyte progenitor cells treated with C2-ceramide decreased CUGBP1 in the nuclear fraction, and hippocampal and cortical tissues collected from neonatal rat challenged with ischemia decreased the Bcl-xL/Bcl-xS ratio. Although this study did not emphasize a direct role of ROS in Bcl-xL gene splicing, both the C2-ceramide model in vitro and the in vivo model in a chemical enhance containing BH4, but lacking BH1 and BH2 domains, Bcl-xS-mediated apoptosis is independent from mechanisms induced by other pro-apoptotic Bcl2 proteins (Lindenboim et al., 2000). However, both Bcl-xS and ΔN-Bcl-xL production occur during apoptosis in a caspase dependent manner (Williott et al., 2011), and Bcl-xS binds directly to Bcl-xL (Lindenboim et al., 2001). Therefore, conditions that enhance Bcl-xS contribute to limiting the pro-survival function of Bcl-xL.

Conversely, another study showed that ROS may lead to increases in Bcl-xL mRNA. C57BL/6 mice that were treated with bilateral common carotid artery occlusion had increased Bcl-xL mRNA levels 24 hours after ischemia (Wu et al., 2003). Since depletion of Bcl-xL is well documented to increase the vulnerability of neurons, these results suggest that there is a protective molecular response against ischemia by modifying the transcription of Bcl-xL. One mechanism may be through regulation of transcription factors. Nuclear factor kappa B (NF-kB) is well-established as a transcription factor that targets the bcl-x gene (Chen et al., 2000). It is known that over-accumulation of mitochondrial ROS can stimulate NF-kB to target genes that promote survival, including bcl-x (Chen et al., 2000; Morgan and Liu, 2011). Lanzillotta et al. (2013) research group demonstrated this connection in a rodent model of ischemia. Mutation of the NF-kB binding site on Bcl-xL’s promoter region led to downregulation of the bcl-x gene, indicating that NF-kB is indeed an important regulator of transcription following ischemia. Similarly, nuclear factor erythroid 2-related factor 2 (Nrf2) may be involved in a protective response to ROS insult. Nrf2 is a transcription factor that is known for its role in antioxidant systems against ROS (Ryoo and Kwak, 2018). Nrf2 remains inactive and bound to Keap1 under conditions of oxidative stress. In response to the process of phosphorylation, Nrf2 dissociates from Keap1 and translocates to the nucleus, where it then binds to antioxidant response elements of target genes (Wu et al., 2013; Deshmukh et al., 2017; Wen et al., 2018). Bcl-x contains an antioxidant response element, resulting in direct binding of Nrf2. The reverse of transcriptional enhancement of Bcl-xL was demonstrated by an siRNA-mediated decrease in Nrf2, leading to subsequent reduction in Bcl-xL mRNA (Niture and Jaiswal, 2013). Through activation of transcription factors such as NF-kB and Nrf2, ROS can influence the transcription of Bcl-xL. However, it remains unclear what additional factors may lead to Bcl-xL mRNA upregulation versus downregulation.

Conclusion

Bcl-xL is a key protein that enhances neuronal function by regulating energy metabolism, neurotransmission, and the survival or death of neuroprogenitors and post-mitotic neurons. The activity and abundance of Bcl-xL is controlled by oxidative stress: ROS control the post-translational modification of Bcl-xL including its proteolytic cleavage and residue phosphorylation (Figure 1). These modifications alter the availability of functional Bcl-xL and its activity. It has been shown that ROS also play a part in the transcriptional regulation of Bcl-xL (Figure 1). Therefore, understanding ROS-mediated Bcl-xL alterations are important to further elucidate mechanisms of ROS-associated brain disease, and approaches that manipulate ROS may be an effective way to manipulate Bcl-xL function and abundance in the brain.

Author contributions: HAP, KB and EAJ wrote this manuscript. All authors approved the final manuscript.

Conflicts of interest: The authors declare no conflicts of interest.

Financial support: None.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Open peer reviewers: Elizabeth D. Kirby, Ohio State University, USA; Hospital Universitario Central de Asturias, Spain.

Additional file: Open peer review reports 1 and 2.

References

Alavian KN, Beutner G, Lazaro E, Sacchetti S, Park HA, Licznerski P, Li H, Nabili P, Hockensmith K, Graham M, Porter GA Jr, Jonas EA (2014) An uncoupling channel within the c-subunit ring of the F1FO ATP synthase is the mitochondrial permeability transition pore. Proc Natl Acad Sci U S A 111:10580-10585.

Alavian KN, Li H, Collis L, Bonanni L, Zeng L, Sacchetti S, Lazaro E, Nabili P, Flaherty B, Graham M, Chen Y, Messeri SM, Margiotta MA, Rahner C, McNay E, Shore GC, Smith PJ, Hardwick JM, Jonas EA (2011) Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase. Nat Cell Biol 13:1224-1233.

Arena G, Gelmetti V, Torsosantucci L, Vignone D, Lamorte G, De Rosa P, Cilia E, Jonas EA, Volente EM (2015) PINK1 protects against cell death induced by mitochondrial depolarization, by phosphorylating Bcl-xL and impairing its pro-apoptotic cleavage. Cell Death Differ 20:920-930.
Barusah P, Beauchemin M, Hebert J, Bertrand R (2016) Dynamic Bcl-xL (S49) and (S62)
Phosphorylation/dephosphorylation during mitosis prevents chromosome instability
and aneuploidy in normal human diploid fibroblasts. PLoS One 11:e0159901.
Bassanez, M, Zhu B, Chen X, Makgwe, F, Foucher, V, Brandt M, Bak, H, Hardwick JM, Zigmond J (2001) Pro-apoptotic clefts products of Bcl-xL form cytochrome c-conducing pores in pure lipid membranes. J Biol Chem 276:31083-31091.
Billa F, Hauck I, Konczyk F, Rao V, Shen J, Mkw (2011) PTEN-inducible kinase 1 (PINK1) for
neurodegenerative disorders. Nature Rev Neurosci 12:508-518.
Bax JN, Tai CT, Tung ML, Dichmann DS, Wang M, Dussmann H, Woods I, Courtney MJ, Ward MW, Prehn JH (2003) Mitochondrially localized active caspase-9 and caspase-3
and its apoptotic activity requires localization of Bcl-x(S) to the mitochondria and its
expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 23:2687-2695.
Bekkers M, Beckers C, Otten J, Dijkema R, Nijmont C, de Weger RA, Coomans SK, Clerinx J, Hulstaert F (2007) Dynamic Bcl-xL (S49) and (S62)
depletion and functional switching during stress response in A572 cells. Cell Death Differ 14:1013-1025.
Bengtson K, Alavian KN, Dayhoff-Brannigan M, Zou S, Pineda FJ, O'Rourke B, Ko YH, Pedersen PL, Alavian KN (2019) Parkinson’s disease protein
D3 regulates ATP synthase protein components to increase neuronal process outgrowth. Cell Death Dis 10:469.
Ben-Aroya A, Hsu YT, Li H, Chen YB, Aon MA, Hsu YT, Soane L, Teng X, McCaffery JM, Cheng WC, Qi B, Li H, Chandra D, Tang DG (2003) Mitochondrially localized active caspase-9 and caspase-3 result mostly from the stabilization of the cytosol and partly from caspase-mediated activation in the organelle. Lack of evidence for Apaf-1-mediated procaspase-9 activation in the mitochondria. J Biol Chem 278:17408-17420.
Chen CD, Huang YC, Lee YC, Lin SC, Lin S, Lai TF, Yang CC, Chuang SC, Chen YC, Chiang Y, Chen YC, Huang HY, Lu YC, Liao CH, Huang JY, Lin CT (2016) Induced expression of the apoptosis inhibitor Bcl-x(L) in PC12 cells. Oncogene 16:6829-6837.
Chen R, Park HA, Matsuokay N, Niu Y, Licznerski P, Wu J, Miranda R, Graham SH, Tang DG (2018) Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. J Biol Chem 293:5431.
Chen R, Park HA, Jonas EA (2017) Dynamic Bcl-xL, a therapeutic target for neuroprotection. Neuro Regen Res 12:1791-1794.
Chen R, Park HA, Matsuokay N, Broman K, Davis RJ, Licznerski P, Crowe KM, Jonas EA (2013) Dynamic Bcl-xL, a therapeutic target for neuroprotection. J Cell Physiol 228:2144-2155.
Chen R, Park HA, Jonas EA (2016) Bcl-xL is essential for the survival and function of differentiated neurons in the cortex that control complex behaviors. J Neurosci 36:5448-5461.
Chen R, Park HA, Jonas EA (2017) Dynamic Bcl-xL, a therapeutic target for neuroprotection. Neuro Regen Res 12:1791-1794.
Chen X, Li L, Chen S, Li H, Pan Y, Wang L, Sun L, Tang Y, Wang X, Chen S, Li H, Cao Y, Wang H, Yuan X, Tang D, Chen L, Guo D, Xu X (2018) Targeting of mitochondria by POBN alleviates nonalcoholic steatohepatitis. Hepatology 68:2019-2033.
Chen X, Wang X, Xu Y, Lai S, Li H, Shi H, Chen Y, Wang J, Zhao Y, Wang X (2017) Synergistic anti-inflammatory effects of POBN and PBMC treatment in LPS-induced RAW 264.7 macrophages. Inflammopharm 15:23-30.
Chen X, Yu C, Jia Y, Zhang X, Guo J, Wang Y, Shao X, Zhang X, Wang Y, Wang X (2017) Suppression of the pro-inflammatory response by POBN treatment in LPS-stimulated RAW 264.7 macrophages. Inflammopharm 15:23-30.
Chen Y, Park HA, Jonas EA (2016) Bcl-xL is essential for the survival and function of differentiated neurons in the cortex that control complex behaviors. J Neurosci 36:5448-5461.